{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DMX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMX\",,,,,undefined,":{"symbol":"DMX","market":"US","secType":"STK","nameCN":"DoubleLine Multi-Sector Income ETF","latestPrice":49.6434,"timestamp":1745847001810,"preClose":49.6434,"halted":0,"volume":54,"delay":0,"floatShares":520001,"shares":520001,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"04-28 11:04:30 EDT","open":49.6434,"high":49.6434,"low":49.6434,"amount":2673.54,"amplitude":0,"askPrice":49.65,"askSize":100,"bidPrice":49.4,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745870400000},"marketStatusCode":2,"adr":0,"exchange":"AMEX","adjPreClose":49.6434,"sharesOutstanding":520001,"nav":49.3477,"aum":25660847.45,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":49.65,"preClose":49.6434,"latestTime":"16:05 EDT","volume":2,"amount":99.2868,"timestamp":1745611510376},"volumeRatio":0.002018},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMX\",,,,,undefined,":{"symbol":"DMX","floatShares":520001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.002018,"shares":520001,"dividePrice":3.03917,"high":49.6434,"amplitude":0,"preClose":49.6434,"low":49.6434,"week52Low":48.45,"pbRate":"--","week52High":50.4662,"institutionHeld":0,"latestPrice":49.6434,"eps":0,"divideRate":0.06122,"volume":54,"delay":0,"ttmEps":0,"open":49.6434,"prevYearClose":50.0239,"prevWeekClose":49.6434,"prevMonthClose":49.8,"prevQuarterClose":49.8,"fiveDayClose":48.9963,"twentyDayClose":49.8839,"sixtyDayClose":50.305},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DMX\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DMX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530460381","title":"FDA Endorsement Boosts Dimerix’s DMX-200 Path to Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2530460381","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530460381?lang=en_us&edition=fundamental","pubTime":"2025-04-28 08:17","pubTimestamp":1745799432,"startTime":"0","endTime":"0","summary":"Dimerix Limited ( ($AU:DXB) ) has issued an announcement. Dimerix Limited announced a significant development in its Phase 3 clinical trial for DMX...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fda-endorsement-boosts-dimerixs-dmx-200-path-to-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fda-endorsement-boosts-dimerixs-dmx-200-path-to-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DMX"],"gpt_icon":0},{"id":"2528216127","title":"DoubleLine Opportunistic Core Bond ETF Marks First Three Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2528216127","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528216127?lang=en_us&edition=fundamental","pubTime":"2025-04-18 01:35","pubTimestamp":1744911300,"startTime":"0","endTime":"0","summary":"DBND Generated Higher Return with Less Risk than Benchmark and Fund Category Average. TAMPA, Fla., April 17, 2025 /PRNewswire/ --The DoubleLine Opportunistic Core Bond ETF , an actively managed exchange-traded fund launched March 31, 2022, on the NYSE Arca electronic exchange, now has a three-year track record.For the three years ended March 31, 2025, the DoubleLine Opportunistic Core Bond ETF  delivered an annualized return of 1.66% . DBND's benchmark, the Bloomberg US Aggregate Bond Index , produced an annualized return of 0.52% for the same period. The average annualized return for DBND's Morningstar fund category, Intermediate Core-Plus Bond, 0.92%. DBND delivered that excess return with less risk than the benchmark and the fund category average as measured by return volatility and maximum drawdown.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/doubleline-opportunistic-core-bond-etf-173500595.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/doubleline-opportunistic-core-bond-etf-173500595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DABS","US30Y.BOND","NAV","US2Y.BOND","FDN","BK4585","CAPE","DCMT","US6M.BOND","CMBS","US5Y.BOND","DSL","DFVE","DMX","US12M.BOND","US3Y.BOND","BK4588","DCRE","DMBS","US10Y.BOND","BK4550","US7Y.BOND"],"gpt_icon":0},{"id":"2516136766","title":"Dimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2516136766","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516136766?lang=en_us&edition=fundamental","pubTime":"2025-03-04 11:32","pubTimestamp":1741059169,"startTime":"0","endTime":"0","summary":"Dimerix  received an upfront payment of roughly AU$3.2 million from FUSO Pharmaceutical Industries in relation to a license agreement for hypertension and kidney disease drug candidate DMX 200, according to a Tuesday filing with the Australian bourse.Under the agreement, FUSO has the exclusive rights to commercialize DMX 200 for Focal Segmental Glomerulosclerosis kidney disease in Japan. Dimerix retains all rights to commercialize DMX-200 in all territories other than those covered by FUSO, and two other licensees, namely Advanz Pharma and Taiba, per the filing.The Australian biopharmaceutical company is entitled to receive further payments once it reaches certain development milestones.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","BK7508","XAO.AU","BK7501","DMX","XJO.AU","DXB.AU","BK7067"],"gpt_icon":0},{"id":"2516692168","title":"Dimerix posts modest gain as first Japanese payment for DMX-200 lands","url":"https://stock-news.laohu8.com/highlight/detail?id=2516692168","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516692168?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:46","pubTimestamp":1741045560,"startTime":"0","endTime":"0","summary":"Dimerix Ltd  has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries as part of a deal struck in January.Under that deal, FUSO and Dimerix teamed up to develop and commercialise Dimerix’s drug ‘DMX-200’ in Japan, which treats Focal Segmental Glomerulosclerosis , a scar tissue disease affecting kidneys.The $3.2M upfront payment is the first of multiple Dimerix expects, with up to $30M in payments possible under the FUSO deal. Another $4.1M is expected in the next six to 12 weeks as the first clinical trial in Japan begins.That timeframe is based on the certainty FUSO is already identifying trial sites ahead of the ‘ACTION3’ trial. Notably, FUSO is also responsible for all trial costs.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/dimerix-posts-modest-gain-as-first-japanese-payment-for-dmx-200-lands-2025-03-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","BK7501","FSGS","BK7508","DMX","DXB.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DMX\",params:#limit:5,,,undefined,":[{"date":"2025-04-01","symbol":"DMX","amount":0.28018,"announcedDate":"2025-03-31","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-01","defaultRemindTime":1743514200000,"name":"DoubleLine Multi-Sector Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-07","payableDate":"2025-04-01","currency":"USD","dateTimestamp":1743480000000,"payDate":"2025-04-07"},{"date":"2025-03-03","symbol":"DMX","amount":0.255266,"announcedDate":"2025-02-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-03","defaultRemindTime":1741012200000,"name":"DoubleLine Multi-Sector Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-07","payableDate":"2025-03-03","currency":"USD","dateTimestamp":1740978000000,"payDate":"2025-03-07"},{"date":"2025-02-03","symbol":"DMX","amount":0.268541,"announcedDate":"2025-01-31","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-03","defaultRemindTime":1738593000000,"name":"DoubleLine Multi-Sector Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-07","payableDate":"2025-02-03","currency":"USD","dateTimestamp":1738558800000,"payDate":"2025-02-07"},{"date":"2024-12-23","symbol":"DMX","amount":0.209071,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"DoubleLine Multi-Sector Income ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DMX\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.209071,"currency":"USD"},{"executeDate":"2025-02-03","recordDate":"2025-02-03","paymentDate":"2025-02-07","value":0.268541,"currency":"USD"},{"executeDate":"2025-03-03","recordDate":"2025-03-03","paymentDate":"2025-03-07","value":0.255266,"currency":"USD"},{"executeDate":"2025-04-01","recordDate":"2025-04-01","paymentDate":"2025-04-07","value":0.28018,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DMX\",market:\"US\",delay:false,,,undefined,":{}}}